Trial Outcomes & Findings for Gynecologic Brachytherapy-Specific Educational Video (NCT NCT04363957)
NCT ID: NCT04363957
Last Updated: 2025-10-14
Results Overview
Primary Analysis based on Intention-to-Treat population, defined as all individuals who were randomized to arm A or arm B. A Likert-scale study specific questionnaire (no unabbreviated scale title, Likert-scale is a general untitled tool) is used to calculate satisfaction score. Using the brachytherapy specific questionnaire, the study team will examine three patient reported time points for impact: baseline, after the consent process, and prior to the last brachytherapy procedure. For primary endpoint, a two-sample t-test will be used to compare differences of satisfaction scores at two time points (baseline and following consent process) between groups. The reporting scale is the following: Strongly disagree (1); Disagree (2); Uncertain (3); Agree (4); Strongly agree (5) Minimum: 1; Maximum: 5. Questionnaire had 12 questions. Minimum possible score is 12; Maximum possible score is 60. Higher score means higher satisfaction.
COMPLETED
NA
80 participants
Baseline
2025-10-14
Participant Flow
Participant milestones
| Measure |
Standard Consent
Patients only receive the standard brachytherapy consent process
Standard Brachytherapy Consent Process: Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
|
Standard Consent and Video Intervention
Patients receive the standard brachytherapy consent process and the addition of an informational video about brachytherapy
Brachytherapy video: Patients will watch a video that contains information about brachytherapy
Standard Brachytherapy Consent Process: Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
|
|---|---|---|
|
Overall Study
STARTED
|
40
|
40
|
|
Overall Study
COMPLETED
|
29
|
28
|
|
Overall Study
NOT COMPLETED
|
11
|
12
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Gynecologic Brachytherapy-Specific Educational Video
Baseline characteristics by cohort
| Measure |
Standard Consent
n=29 Participants
Patients only receive the standard brachytherapy consent process
Standard Brachytherapy Consent Process: Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
|
Standard Consent and Video Intervention
n=28 Participants
Patients receive the standard brachytherapy consent process and the addition of an informational video about brachytherapy
Brachytherapy video: Patients will watch a video that contains information about brachytherapy
Standard Brachytherapy Consent Process: Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
|
Total
n=57 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
58 Years
n=5 Participants
|
60 Years
n=7 Participants
|
59 Years
n=5 Participants
|
|
Sex: Female, Male
Female
|
29 Participants
n=5 Participants
|
28 Participants
n=7 Participants
|
57 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
5 Participants
n=5 Participants
|
7 Participants
n=7 Participants
|
12 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
22 Participants
n=5 Participants
|
20 Participants
n=7 Participants
|
42 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
|
Primary Cancer
Cervix
|
15 Participants
n=5 Participants
|
16 Participants
n=7 Participants
|
31 Participants
n=5 Participants
|
|
Primary Cancer
Uterine
|
13 Participants
n=5 Participants
|
10 Participants
n=7 Participants
|
23 Participants
n=5 Participants
|
|
Primary Cancer
Vagina
|
1 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: BaselinePrimary Analysis based on Intention-to-Treat population, defined as all individuals who were randomized to arm A or arm B. A Likert-scale study specific questionnaire (no unabbreviated scale title, Likert-scale is a general untitled tool) is used to calculate satisfaction score. Using the brachytherapy specific questionnaire, the study team will examine three patient reported time points for impact: baseline, after the consent process, and prior to the last brachytherapy procedure. For primary endpoint, a two-sample t-test will be used to compare differences of satisfaction scores at two time points (baseline and following consent process) between groups. The reporting scale is the following: Strongly disagree (1); Disagree (2); Uncertain (3); Agree (4); Strongly agree (5) Minimum: 1; Maximum: 5. Questionnaire had 12 questions. Minimum possible score is 12; Maximum possible score is 60. Higher score means higher satisfaction.
Outcome measures
| Measure |
Standard Consent
n=29 Participants
Patients only receive the standard brachytherapy consent process
Standard Brachytherapy Consent Process: Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
|
Standard Consent and Video Intervention
n=28 Participants
Patients receive the standard brachytherapy consent process and the addition of an informational video about brachytherapy
Brachytherapy video: Patients will watch a video that contains information about brachytherapy
Standard Brachytherapy Consent Process: Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
|
|---|---|---|
|
Patient Reported Satisfaction
|
54 satisfaction score at baseline
Interval 45.0 to 54.0
|
55 satisfaction score at baseline
Interval 49.0 to 55.0
|
SECONDARY outcome
Timeframe: BaselineSatisfactory scores at three time points will be analyzed using a mixed effect model for repeated measures (MMRM) to assess satisfactory scores trajectories between two arms. The MMRM model will include terms for time, consent arm, baseline score, arm-by-time interaction, baseline score by time interaction, plus covariates that include age, stage. Time will be treated as categorical. If values of last two time points are similar, analysis of covariance model (ANCOVA) will be used to model the change in satisfactory scores. The mean of the last two time points will be calculated. That is, the after consent score (mean values) will be regressed upon baseline score and consent arms. Patient treatment-related anxiety between groups, defined as National Comprehensive Cancer Network (NCCN) distress score, are also collected at three time points and will be analyzed using the same strategy. The NCCN distress scale is from 0 (min) -10 (max) with 10 being a value that is more distress- worse.
Outcome measures
| Measure |
Standard Consent
n=29 Participants
Patients only receive the standard brachytherapy consent process
Standard Brachytherapy Consent Process: Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
|
Standard Consent and Video Intervention
n=28 Participants
Patients receive the standard brachytherapy consent process and the addition of an informational video about brachytherapy
Brachytherapy video: Patients will watch a video that contains information about brachytherapy
Standard Brachytherapy Consent Process: Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
|
|---|---|---|
|
Treatment Related Anxiety
|
4 anxiety score at baseline
Interval 2.0 to 7.0
|
4 anxiety score at baseline
Interval 1.0 to 6.0
|
Adverse Events
Standard Consent
Standard Consent and Video Intervention
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Jyoti Mayadev
University of California, San Diego
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place